Garya Lyons News Today

O Neil Global Advisors Inc. decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 30.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,535 shares of the company’s stock after selling 663 shares […]

Great Lakes Advisors LLC raised its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 0.9% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 163,485 shares of the company’s stock after purchasing an additional 1,528 shares during the period. Great Lakes Advisors LLC owned about 0.17% […]

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by investment analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Thursday. Other analysts also recently issued reports about the company. Royal Bank of Canada decreased their price target on Neurocrine Biosciences from $128.00 to $121.00 and […]

Natixis lifted its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 36.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 22,426 shares of the company’s stock after acquiring an additional 6,001 shares during the period. Natixis’ holdings […]

Natixis lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 36.5% in the second quarter, according to its most recent filing with the SEC. The fund owned 22,426 shares of the company’s stock after acquiring an additional 6,001 shares during the period. Natixis’ holdings in Neurocrine Biosciences were worth $2,115,000 […]

Lisanti Capital Growth LLC purchased a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 13,590 shares of the company’s stock, valued at approximately $1,282,000. Other institutional investors have also modified their holdings […]

Geode Capital Management LLC grew its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 6.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,523,408 shares of the company’s stock after purchasing an additional 87,671 shares during […]

Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) – Analysts at Cantor Fitzgerald increased their FY2024 earnings per share (EPS) estimates for Neurocrine Biosciences in a report released on Wednesday, November 1st. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will earn $4.85 per share for the year, up from their prior forecast of […]

AtonRa Partners decreased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 6.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,855 shares of the company’s stock after selling 456 shares during the period. Neurocrine […]

Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price lifted by BMO Capital Markets from $100.00 to $111.00 in a report released on Wednesday morning, Marketbeat Ratings reports. BMO Capital Markets currently has a market perform rating on the stock. Several other equities research analysts have also weighed in on the company. Jefferies Financial […]